“It’s the prices, stupid,” Uwe E. Reinhardt and authors famously wrote in their 2003 article describing the cause of high health care spending in the United States.1 Since then, multiple large analyses have confirmed that the prices of labor and goods, including pharmaceuticals and administrative costs, more so than differences in utilization, are the primary drivers of high health care spending.2,3
Assessing the impact of the CMS price transparency rule on patients with prostate cancer
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Resident physician, Department of Radiation Oncology, University of North Carolina at Chapel Hill
Assistant professor, Department of Radiation Oncology, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Table of Contents
YOU MAY BE INTERESTED IN
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
Christy Erickson was seven years old when her mom lost a three-year battle with breast cancer.
Two decades after uncovering the role of EGFR mutations in lung cancer, scientists are still grappling with lingering research questions.
Lei Zheng was named executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and vice president for oncology for the University of Texas Health Science Center at San Antonio.
Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.
